Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several mechanistic, dosing, grapefruit juice, and warfarin/digoxin/side-effect claims are not supported and/or conflict with the provided FDA label excerpts. Multiple omissions also reduce label fidelity.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels.
Mechanism of action as HMG-CoA reductase inhibitor (Section 12.1) and indicated to reduce LDL-C/total-C and TG levels (Section 1.2).
Lipitor works by reducing the production of low-density lipoprotein (LDL) cholesterol.
Mechanism of action (Section 12.1) and reductions in LDL-C (Section 1.2, Section 14.2). (Note: label describes inhibition of HMG-CoA reductase leading to reduced precursor sterols including cholesterol.)
By lowering LDL levels, Lipitor helps to prevent the buildup of plaque in arteries, which can lead to heart attacks, strokes, and other cardiovascular events.
Indications to reduce risk of MI and stroke and revascularization/angina (Section 1.1) and LDL-C reduction (Section 1.2, Section 14.2).
Lipitor is available in tablets and capsules.
Partially supported: label excerpt specifies white film-coated tablets containing 10/20/40/80 mg (Section 3). (No capsule dosage form is supported in provided excerpts.)
The recommended starting dose for adults is 10 mg or 20 mg once daily.
Recommended starting dose is 10 or 20 mg once daily (Section 2.1).
A doctor may adjust the Lipitor dose based on individual needs and response to treatment.
Dosage should be individualized with adjustments at intervals of 4 weeks or more (Section 2.2). (Provided excerpts do not explicitly state individualized adjustments for adults, but dose adjustment concept is present.)
For primary hyperlipidemia, the recommended starting dose for adults is 10 mg or 20 mg once daily.
Hyperlipidemia starting dose 10 or 20 mg once daily (Section 2.1) and indication for primary hypercholesterolemia (Section 1.2).
For homozygous familial hypercholesterolemia, the recommended dose is 40 mg to 80 mg once daily.
Label excerpt states dosage in homozygous FH is 10 to 80 mg daily and does not specify 40 to 80 mg as the recommended dose (Section 2.3). (Therefore this statement is not fully supported.)
Grapefruit juice can increase Lipitor levels in the bloodstream.
Grapefruit juice can increase plasma concentrations of atorvastatin, especially with excessive intake (>1.2 liters per day) (Section 7.2).
Common side effects of Lipitor include nausea, vomiting, and abdominal pain.
Nausea reported (Section 6.1). However, vomiting and abdominal pain are not explicitly listed in provided excerpt for common adverse reactions.
Unsupported Statements
Lipitor works by reducing the production of low-density lipoprotein (LDL) cholesterol.
Label excerpt states mechanism as HMG-CoA reductase inhibition and indicates reductions in LDL-C, but does not explicitly say it 'reduces production of LDL cholesterol.'
Lipitor is available in tablets and capsules.
Provided label excerpt only specifies tablets (Section 3); capsules are not supported.
The recommended starting dose for adults is taken once daily in the evening.
Label excerpt states once daily at any time of the day, with or without food (Section 2.1); no evening restriction.
If cholesterol levels improve, a doctor may increase the Lipitor dose to achieve optimal results.
Provided excerpts do not describe dose increases based on improvement of cholesterol levels for adults.
If side effects occur, a doctor may decrease the Lipitor dose or switch to a different medication.
Provided excerpts do not describe switching to different medication; dose reduction/withdrawal is discussed for transaminase elevations, but switching due to side effects is not supported in excerpts.
For hypertriglyceridemia, the recommended starting dose for adults is 10 mg or 20 mg once daily.
Label excerpt supports starting dose 10 or 20 mg once daily for hyperlipidemia broadly (Section 2.1) and indication for elevated serum TG levels (Section 1.2), but it does not explicitly tie the 10/20 mg starting dose specifically to hypertriglyceridemia.
For homozygous familial hypercholesterolemia, the recommended dose is 40 mg to 80 mg once daily.
Label excerpt states dosage is 10 to 80 mg daily for homozygous FH (Section 2.3); it does not specify 40 to 80 mg as the recommended dose.
Consuming high-fat foods can reduce the absorption of Lipitor.
Provided label excerpt states that food decreases rate/extent of absorption but LDL-C reduction is similar with/without food (Section 12.3); it does not specify high-fat foods specifically.
Reduced absorption from high-fat foods may reduce Lipitor effectiveness.
Label excerpt states LDL-C reduction is similar with/without food (Section 12.3), which does not support that reduced absorption reduces effectiveness.
Lipitor is a pregnancy category X medication.
Provided label excerpts do not include pregnancy category labeling (e.g., 'Category X').
It is not known whether Lipitor passes into breast milk.
Label excerpt states 'It is not known whether atorvastatin is excreted into human milk' (Section 4.4), which matches this statement; thus this is actually supported as written. (No action needed.)
If kidney or liver disease is present, a doctor may need to adjust the Lipitor dose to prevent adverse effects.
Label excerpt says renal disease does not affect plasma concentrations nor LDL-C reduction; thus dosage adjustment is not necessary in renal impairment (Section 2.5). For hepatic impairment, active liver disease is a contraindication (Sections 4.1 and 8.6) but the excerpt does not describe a need for dose adjustment in liver disease.
Lipitor can interact with warfarin.
Provided label excerpts list specific interactions including fibric acid derivatives, niacin, cyclosporine, strong CYP3A4 inhibitors (clarithromycin, HIV protease inhibitors, itraconazole) and grapefruit juice (Sections 7 and 7.2). Warfarin is not mentioned in provided excerpts.
When taken with warfarin, Lipitor can increase the risk of bleeding.
No provided label excerpt mentions warfarin or bleeding risk.
Lipitor can interact with digoxin.
No provided label excerpt mentions digoxin.
Lipitor can increase digoxin levels in the bloodstream.
No provided label excerpt mentions digoxin.
Increased digoxin levels from Lipitor may lead to increased side effects.
No provided label excerpt mentions digoxin or related side effects.
An overdose of Lipitor may cause nausea.
Provided label excerpts include adverse reactions but do not provide overdose manifestations.
An overdose of Lipitor may cause vomiting.
No provided label excerpt provides overdose symptoms.
An overdose of Lipitor may cause abdominal pain.
No provided label excerpt provides overdose symptoms.
Contradictions
Low
AI Statement
The recommended starting dose for adults is taken once daily in the evening.
Label Reference
LIPITOR can be administered as a single dose at any time of the day (Section 2.1).
Low
AI Statement
Lipitor is available in tablets and capsules.
Label Reference
Only tablets are specified in provided excerpt (Section 3); capsules are not supported and may be inaccurate.
Low
AI Statement
Reduced absorption from high-fat foods may reduce Lipitor effectiveness.
Label Reference
Food decreases rate/extent of absorption but LDL-C reduction is similar with/without food (Section 12.3).
Low
AI Statement
Lipitor is a pregnancy category X medication.
Label Reference
Provided label excerpts do not state pregnancy category X; contraindication for pregnancy/may cause fetal harm is stated (Sections 4.3 and 8.1).
Important Omissions
Approved indication details beyond hyperlipidemia and general cardiovascular prevention (e.g., specific cardiovascular outcome reductions and adjunct-to-diet context) were not accurately stated; only a general plaque/MI/stroke narrative was provided.
Importance:
Moderate
Boxed warning content (if any) and key warnings/precautions relevant to safety (e.g., skeletal muscle/rhabdomyolysis, liver dysfunction) were not discussed.
Importance:
Moderate
Key administration flexibility (any time of day) and interval for dose adjustments (e.g., 4 weeks or more) were not included.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Statements about warfarin/digoxin interactions, pregnancy category labeling, and overdose symptoms are unsupported by the provided label excerpts; timing for dosing and food effects contain misleading elements. These inaccuracies could affect safety decisions or counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Multiple unsupported claims (notably warfarin/digoxin interactions, overdose manifestations, capsule formulation, and specific dose ranges/timing) and at least one misleading food-effect statement.
Suggested Improvement
Restrict claims to the provided label excerpt: remove warfarin/digoxin interaction and overdose symptom claims, correct dosing timing to 'any time of day', align homozygous FH dosing to '10 to 80 mg daily', and ensure food/gut-absorption statements match 'food decreases absorption rate/extent but LDL-C reduction is similar with/without food.'